Kornimate/medical-research-clean huggingface dataset:
analysis of non-invasive ventilatory support modes: high flow nasal cannula and non-invasive ventilation

Conditions: Asthma Acute

Summary: this study compares two types of noninvasive treatments for asthma attacks with the objective of analyzing the efficacy of each therapy during the period of exacerbations in infants and asthmatics hospitalized.

a randomized clinical trial, where it will be established, treatment in hospitalized asthma patients in the infirmary and emergency room of the hospital infantil cândido fontoura. the children eligible for the protocol, after signing the terms of consent and assent, will be randomized for treatment in 2 groups (gi - bilevel and gii - high flow nasal cannula). after the evaluations are started: feb1, volume expired in the first second; peak flow, vital signs and calculated pulmonary asthma score, pulmonary asthma severity score, pulmonary index score, and therapy application. the n to be considered for the study of 20 individuals per group. group therapy i will be applied in diaphragmatic re-education exercises 3 x 10 breaths, after non-invasive ventilation, with parameters 12 cm h2o ipap and epap 8 cm h2o, for 45 minutes, according to patient tolerance, interface, with full face mask after treatment, reassessment of vital signs and measurements of peak flow, fev1 and severity scores. the gii will be established therapy with high-flow nasal cannula with dosage and cannula calculated according to the child's weight and respiratory rate at the time of evaluation, ranging from 2 l / min to 30 l / min. flow. the therapy will begin with diaphragmatic exercises 3 x 10 breaths, after 45 minutes of the installation of the therapy that is continuous, will be performed a reassessment of vital signs and peak flow, feb, severity scores. during the hospitalization time of the child will be carried out the daily treatment, therapy chosen for each patient for 45 minutes in the case of gi and the gii group daily follow-up and adjustment of flow dosage, also evaluated the vital signs, vital signs and peak flow, feb, gravity scores. at the time of hospital discharge, the evaluations will be performed and data such as inhaled corticosteroid use, oxygen use in days and inspired fraction, hospitalization days, hospital costs, as well as vital signs, vital signs and peak flow, fev, scores of gravity.

Eligibility criteria:
inclusion criteria: * age between 5 and 16 years; * both genders; * be in the presence of the bronchospasm crisis; * be admitted to hicf hospital; * have signed the search terms exclusion criteria: * having associated heart disease; * neurological/cognitive impairment; * have severe respiratory insufficiency detected by severity scores; * intolerance to any type of treatment

Keywords: asthma high flow nasal cannula non invasive ventilation
effects of virtual reality rehabilitation and muscle energy technique in patients with patellofemoral pain syndrome.

Conditions: Patellofemoral Pain Syndrome; Knee Pain Chronic

Summary: the aim of this randomized controlled trial is to determine the effects of virtual reality rehabilitation and muscle energy techniques in patients with patellofemoral pain syndrome for reducing pain, enhancing knee range of motion and improve functional activities.

muscle energy technique is defined as a manual treatment in which patient produces a contraction in a precisely controlled position and direction against the counterforce applied by a manual therapist. applications of met to stretch and increase myofascial tissue extensibility seem to affect viscoelastic and plastic tissue property. virtual reality generates a virtual world in three dimensional space through a computer simulation that stimulates user senses, such as sight and hearing, making users feel as if they are immersed in it. vrbr is effective in improving knee pain, rom, strength and functions. immersive vr is more appropriate for pain reduction, improving range of motion and functional activities. it distracts the patient and allows to perform active and rehabilitation exercises to reduce cognitive attention in pain and avoidance behavior.

Eligibility criteria:
inclusion criteria: * age group 18-40 * both males and females * retropatellar or anterior knee pain for atleast past 3 months * having knee pain in atleast 2 activities among stair ascent and descent,squatting over 90 degrees, running,jumping,kneeling and prolong sitting with knees flexed. * experience pain in one of the following knee tests; a) pain on patellar grinding test, b) pain on apprehension test, c) pain during resisted extension of the knee during 90 degree flexion exclusion criteria: * cervical radiculopathy * neurological disorder * pregnancy * rheumatoid arthritis * hip or ankle injuries * patellar instabilities * meniscal or ligament tear * who have visual or auditory problems * with cognitive issues * previous surgery related to lower limbs/ radiculopathy * having received knee injections of corticosteroids or hyaluronic acid * knee osteoarthritis * drug use that affects the balance during the past 72 h.

Keywords: muscle energy technique virtual reality technique knee pain
apnoea-hypopnoea-indices determined via continuous positive airway pressure vs those determined by polysomnography

Conditions: Sleep Apnea Syndromes

Summary: to date, no published systematic review and meta-analysis has compared ahi-cpapflow and ahi-psggold. therefore, the primary objective of this study is to compare published data for ahi-psggold and ahi-cpapflow in patients treated by cpap.

the secondary objectives are to evaluate, in a manner similar to the primary objective, data for apnoea indices (ai), hypopnoea indices (hi), respiratory disturbance indices (rdi) and respiratory effort related arousals (reras) and to perform subgroup analyses focusing on the inclusion/exclusion of central apnoea patients, bmi levels, cpap device brands, pressure titration modes, use of a predetermined and fixed pressure level or not, and the impact of a 4%-psg desaturation criteria versus 3%-psg on index accuracy.

Eligibility criteria:
inclusion criteria: * all (full scientific) study designs and publication types written in english and reporting bland-altman test results (or other tests suggesting the presence of the required data) between simultaneous, paired, polysomnography (psg)-derived and continuous positive airway pressure (cpap)-derived data describing sleep disordered breathing. exclusion criteria: * duplicates * does not refer to a full scientific article (e.g. case reports are excluded). * meta-analysis * paediatric populations (populations \<18 years are excluded). * absence of appropriate paired results: synchronized polysomnography (psg)-derived and continuous positive airway pressure (cpap)-derived data must be reported for ≥1 of the following measures: apnoea-hypopnoea-indices (ahi), apnoea-indices (ai), hypopnoea-indices(hi), respiratory disturbance index (rdi), respiratory effort related arousals (rera). * absence of appropriate test comparing paired results: the study must use ≥1 of the fol-lowing tests to compare the previously mentioned psg-vs-cpap-derived data: a bland-altman or correlation test, other conformity tests, tests of differences in centrality. * inappropriate psg scoring 1: psg-derived variables must be coded following the american academy of sleep medicine 2007 (or more recent) guidelines. * inappropriate psg scoring 2: psg-derived variables must be scored manually. * inappropriate psg scoring 3: oxygen desaturation level used for scoring must be mentioned and at 3% or 4%. * inappropriate cpap description: brand/device names must be mentioned.

Keywords: apnoea hypopnoea index cpap
physiologic assessment following gadoxetic acid and gadobenate dimeglumine administration

Conditions: Liver Tumor

Summary: the purpose of this study is to prospectively compare the physiologic response of patients who receive either intravenous gadoxetic acid (eovist) or intravenous gadobenate dimeglumine (multihance).

contrast-enhanced hepatic mri is an accepted method for detecting and characterizing liver lesions. liver lesion characterization is fundamental for patient management, because lesions that meet specific imaging criteria for hepatocellular carcinoma (hcc) are assumed to be hcc without tissue confirmation. there are a variety of gadolinium-based contrast agents that are used for this purpose. two of the more commonly utilized are gadoxetic acid (an hepatobiliary contrast agent that permits 20 minute hepatobiliary phase imaging) and gadobenate dimeglumine (a weak hepatobiliary contrast agent that functions generally as an extracellular contrast agent). a recent study by our group has shown that patients who receive intravenous gadoxetic acid are much more likely to experience transient dyspnea after contrast injection that causes them to breathe rapidly through the arterial phase of imaging, degrading image quality. in that study, subjective complaints of dyspnea and respiratory motion artifact on imaging were scored. the investigators did not assess patient physiologic response. the goal of the proposed work is to build on our prior data and to determine whether there are non-invasively measurable physiologic parameters that can support our original study. specifically, the investigators want to determine whether there are predictable changes in spo2, pulse, respiratory periodicity, and respiratory regularity that correlate with arterial phase image degradation and patients complains of dyspnea. both contrast agents to be assessed in this study are fda approved with at least 4 years of post-marketing experience documenting safety and efficacy. the investigators will not be changing or altering our clinical approach in any way as a part of this study.

Eligibility criteria:
inclusion criteria: * patients 18 years old and older * patients scheduled for mri examination at the university of michigan hospital * patients receiving either multihance or eovist contrast agents during their clinical mri examination exclusion criteria: * patients under 18 years of age * patients who will not receive multihance or eovist as part of their clinical mri examination

Keywords: mri eovist multihance
osa screen negative with spinal duramorph

Conditions: Respiratory Depression

Summary: non emergent scheduled cesarean sections will be consented to participate in this study of patients who have screened negative for obstructive sleep apnea and who are also bmi\>/= 35 to have capnography monitoring postoperatively. the capnography and pulse oximetry will be initiated in the post anesthesia care unit and be worn for 12-24 hours after delivery. data will be retrieved after that time period in a deidentified fashion. medication usage will be reviewed as well as the standard of care information from the duramorph monitoring will be retrieved.


Eligibility criteria:
inclusion criteria: * osa screen negative per hospital protocol * age 18 or greater * bmi\>35 * consent to participate to wear capnography and pulse oximetry monitoring devices post delivery exclusion criteria: * spanish speaking only * under age 18 * contraindication to receiving drugs utilized in delivery anesthetic

Keywords: obstructive sleep apnea screen negative respiratory depression cesarean section
the amplatzer™ post-infarct muscular vsd occluder humanitarian device exemption (h070005) post approval study

Conditions: Post-Infarction Ventricular Septal Defect

Summary: fda issued a humanitarian device exemption (hde) approval order for the amplatzer™ pivsd occluder (h070005) on january 10, 2017. the conditions of approval require that sjm conduct a post approval study to evaluate the safety and probable benefit of the amplatzer™ pivsd occluder.

this is a multi-center, observational study to evaluate the safety and probable benefit of the amplatzer™ pivsd occluder for use in transcatheter closure of muscular ventricular septal defects following a myocardial infarction in the post approval setting. the study has five endpoints (safety: acute and chronic survival; effectiveness: technical success, acute and chronic closure).two cohorts will be utilized to obtain study endpoint data. the first cohort will be comprised of all available emergency and compassionate pivsd occluder subject data from 2011 until the end of 2016 and these data will be used to determine technical success and acute survival. the second cohort of thirty subjects will be comprised of patients who are successfully implanted with a pivsd occluder from 2011 onward at activated study centers. the index procedure must have occurred \>6 months prior to enrollment. subject identification will occur until data on a minimum of 30 subjects with pivsd occluders for post myocardial infarct vsd and post-procedure echocardiogram available for evaluation of residual shunt by the echocardiography core laboratory have been enrolled. the thirty subject cohort data will be used to determine acute closure, chronic closure, and chronic survival endpoints. the study will be conducted at up to 50 centers in the u.s. the expected duration of enrollment is approximately 4 years. the total duration of the clinical study is expected to be 4.5 years.

Eligibility criteria:
first cohort: patients who have undergone an attempt to close a post-infarct vsd using the amplatzer™ pivsd occluder via emergency and compassionate 2011 until the end of 2016. second cohort: * over 18 years old * patients who have previously been successfully implanted with the amplatzer™ pivsd occluder * for living subjects, the subject or subject's legally authorized representative has provided consent to participate in this study * subject's post-procedure echocardiogram is evaluable and can be sent to the echocardiography core laboratory for residual shunt assessment
study to investigate sleep apnea patients at altitude

Conditions: Obstructive Sleep Apnea Syndrome

Summary: the purpose of the study is to investigate the effect of an altitude sojourn on patients with the obstructive sleep apnea syndrome

previous observations do not allow to draw firm conclusions on the effect of altitude sojourn on sleep, breathing and daytime performance in patients with the obstructive sleep apnea syndrome. furthermore, the susceptibility of sleep apnea patients to high altitude related illness is not known. therefore, the purpose is to study untreated patients with obstructive sleep apnea syndrome living at low altitude during a sojourn of a few days at moderate altitude in order to evaluate the physiologic effects of hypobaric hypoxia in these patients. we hypothesize that: 1. sleep and nocturnal breathing disturbances in untreated osa patients are more pronounced at moderate altitude compared to low altitude. 2. the increase in sleep related breathing disturbances at moderate altitude is due to an increase in central apnea/hypopnea

Eligibility criteria:
inclusion criteria: * obstructive sleep apnea syndrome based on symptoms and a sleep study exclusion criteria: * sleep disorders other than obstructive sleep apnea syndrome * other than mild, stable cardiovascular disease * other than mild lung disease * chronic rhinitis, previous uvulopalatopharyngoplasty * treatment with drugs that affect respiratory center drive * internal, neurologic or psychiatric disease that interferes with sleep quality * previous intolerance to moderate or low altitude \< 2600m
the relationship of hand sensory and strength assessments with functionality and kinesiophobia in individuals with rheumatoid arthritis

Conditions: Disease

Summary: rheumatoid arthritis (ra) is a systemic inflammatory disease that can involve all tissues with synovium. the wrist and hand, which are of great importance in our daily activities, are involved early and specifically because they are rich in synovium, which is the target tissue in ra.in many patients with rheumatoid arthritis, hand and wrist involvement is seen from the early stages of the disease. pain, stiffness and swelling in the joint are accompanied by decreased range of motion and muscle strength.hand functions have a very important place due to the fact that the hand must be used in countless daily life activities.kinesiophobia is defined as a state of fear and avoidance of activity and physical movement caused by painful injury and sensitivity to repeated injury.the aim of this study was to investigate the relationship between hand sensory and strength assessment, functionality and kinesiophobia in individuals with rheumatoid arthritis.

rheumatoid arthritis (ra) is a systemic inflammatory disease that can involve all tissues with synovium. the wrist and hand, which are of great importance in our daily activities, are involved early and specifically because they are rich in synovium, which is the target tissue in ra.in many patients with rheumatoid arthritis, hand and wrist involvement is seen from the early stages of the disease. pain, stiffness and swelling in the joint are accompanied by decreased range of motion and muscle strength.hand functions have a very important place due to the fact that the hand must be used in countless daily life activities.kinesiophobia is defined as a state of fear and avoidance of activity and physical movement caused by painful injury and sensitivity to repeated injury.the aim of this study was to investigate the relationship between hand sensory and strength assessment, functionality and kinesiophobia in individuals with rheumatoid arthritis.thirty patients who were followed up in the rheumatology outpatient clinic of fırat university hospital and diagnosed with ra according to the american college of rheumatology (acr) criteria will be included. spss program will be used in statistical analysis. descriptive statistics will be used for the demographic characteristics of the groups. qualitative variables will be defined by number and quantitative variables will be defined by mean and standard deviation.

Eligibility criteria:
inclusion criteria: * female patients between 18-65 years of age * patients whose medical treatment has been stable for the last 3 months exclusion criteria: * patients who have undergone surgery on the hand and wrist * patients with prosthesis * patients with neurological or orthopedic diseases * patients with another accompanying rheumatic disease * patients with malignancy * pregnant patients

Keywords: hand force assessment hand sensory evaluation romatoid artrit
assessing bioavailability of coq10 supplementation in burn patients

Conditions: Burn Injury

Summary: to test the hypotheses that plasma and intracellular coenzyme q10 levels will decline after burn injury and that ubiquinol supplementation will increase plasma and intracellular coenzyme q10 levels in burn patients. to test the hypothesis that ubiquinol supplementation ameliorates mitochondrial dysfunction/disintegrity and metabolic derangements, and decreases circulating alarmins (a.k.a. endogenous damps) in burn patients as compared with placebo.

based on previous clinical studies and our preliminary preclinical data, we want to test the hypotheses that plasma and intracellular coenzyme q10 levels are decreased after burn injury and that coenzyme q10 (ubiquinol) supplementation reverses or ameliorates insulin resistance, metabolic derangements, mitochondrial dysfunction, and increased circulating damps in burn patients. the aforementioned previous studies and preliminary data warrant a small-scale clinical study to evaluate coenzyme q10 status, and bioavailability and efficacy of coenzyme q10 (ubiquinol) supplementation in burn patients. coenzyme q10 (ubiquinol) supplementation could represent a novel, safe and low-cost strategy to improve the clinical outcome of burn patients. we are conducting a randomized, double-blind, placebo-controlled intervention study with anticipated enrollment of 50 subjects. adult burn patients with 5% or greater of total body surface area (tbsa) burn at the massachusetts general hospital (mgh) burn center will be approached to consider study participation. all enrolled patients will be randomized to receive coenzyme q10 (ubiquinol) supplementation or placebo. blood samples will be used for evaluation of coenzyme q10 concentration, mitochondrial dna copy number, non-mitochondrial damps (e.g., cell-free total dna), and defective neutrophil migration.

Eligibility criteria:
inclusion criteria: * ages eligible for study: 18 years and older, and below 85 yeas old * burn patients with 5% or greater of total body surface area burn * nutrition support: routine oral and/or enteral nutrition * enrolled within one week after burn injury * patient or guardian who is capable of giving full informed consent. * anticipated stay in the mgh burn unit: 5 days or more exclusion criteria: * \< 5% tbsa burn * patients required full parenteral nutrition without oral or enteral nutrition support. * patients with liver disease (bilirubin greater than 3) * patients with thyroid disorders (thyroid disease which currently require treatment) * patients with malignancy under treatment * patients with mental illness who have impaired decision-making capacity (mental illness defined by the presence of psychotropic medications and/or the diagnosis of psychiatric illness at the time of admission.) patients with mental illness can be included unless it is determined by the psychiatrist covering the burn unit that they are unable to consent for themselves for other aspects of their care and treatment.) * patients with hiv\* * pregnancy (as determined by routine admission labs)

Keywords: mgh burn patient adult coq10 ubiquinol
improvement of fish oil in obesity with mild cognitive impairment

Conditions: Obesity; Mild Cognitive Impairment

Summary: eighty-eight patients with obesity with mild cognitive impairment（mci） from the multicenter nutrition and chronic disease cohort, who met the inclusion and exclusion criteria, were selected as study subjects and randomly divided into 2 groups, i.e., the placebo group and the n-3 pufa intervention group. subjects in the intervention group were given supplemental n-3 pufa (supplied in 1.36 g fish oil capsules); the placebo group took placebo (1.36 g/d), and the intervention period was 12 consecutive months. general information, dietary intake, body composition, exercise, overall cognitive function and multidimensional cognitive function, abundance of mycobacterium avium and its metabolites acetic acid and propionic acid content, beige adiposity markers, inflammation-related factors, and lipid metabolism were collected at baseline, at the end of 6 months and at the end of 12 months of the intervention, respectively, and the adherence of the two groups of subjects was also assessed. to analyze the effects of n-3 pufa intervention on cognitive function in patients with obesity with mci and to explore the possible mechanisms.


Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria of obesity and mci; * age between 35 and 80 years old; * no dieting or stop dieting in the last 3 months, no fish oil supplements, or willing to stop self-administration of fish oil 3 months before the intervention; * voluntarily participate in the program with informed consent, and sign the informed consent form. exclusion criteria: * those with neuropsychiatric disorders such as stroke, epilepsy, or schizophrenia; * those with cognitive impairment caused by depression, thyroid disease, traumatic brain injury, drug or alcohol intoxication; * those with a history of cerebrovascular disease or cognitive impairment caused by severe cardiac, hepatic, pulmonary, or renal impairment; * those who are complete vegetarians and are unable to comply with the balanced dietary pattern; * those who suffer from severe angina pectoris, asthmatic bronchitis, severe infections , systemic lupus erythematosus, malignant tumors, and other diseases that may affect one's dietary habits and life; * coeliac disease with lipid malabsorption.